Revenue at global eyecare company Alcon is up 6%, according to its latest financial results.
It has announced its results for the three- and nine-month periods ending September 30, 2025.
A media release said that, for the third quarter of 2025, sales were US$2.6 billion (AU$ 3.98 billion), up 6% on a reported basis and up 5% on a constant currency basis, compared with the same quarter of the previous year.
Vision Care net sales, which include contact lenses and ocular health, reached US$1.2 billion (AU$1.84 billion) in the third quarter, an increase of 7% on a reported basis.
Net sales for contact lenses within the Vision Care segment rose 6% percent to US$707 million (AU$1.08 billion) in the third quarter, representing a 5% increase in constant currency.
The company said the growth was primarily driven by new product innovation and price increases, although it was slightly offset by decreases in sales of legacy products.
“In contact lenses, I was pleased with our results this quarter as we continue to outpace the market,” Alcon CEO Mr David J. Endicott said.
“Our toric modalities in particular delivered double-digit growth in the quarter and are expanding access for astigmatic patients.”
In a conference call, Endicott said Alcon’s proposed acquisition of STAAR Surgical, first announced in August and valued at approximately $1.5 billion (AU$2.3 billion), was now scheduled for a STAAR Surgical shareholder vote on December 19.
Last week, STAAR announced that it had agreed with Alcon to amend its previously announced merger agreement, allowing STAAR to proactively solicit third-party proposals.
Regarding the financial results, ocular health net sales were US$462 million (AU$692 million) in Q3, an increase of 7%.
Growth was led by products for dry eye and glaucoma, the company said, including Systane, Tryptyr and Rocklatan, partially offset by declines in contact lens care.
Surgical net sales, including implantables, consumables and equipment/other, were reported as US$1.4 billion (AU$2.14 billion) in Q3, an increase of 6% on a reported basis and 5% on a constant currency basis compared with the third quarter of 2024.
Reported net sales for the first nine months of 2025 were US$7.6 billion (AU$11.6 billion), up 4% versus the first nine months of 2024.
